Exclusive Interview: Dr. William A. Carter, CEO. Hemispherx Biopharma, Inc. (AMEX:HEB) Print E-mail
By M.E.Garza   
Friday, 12 June 2009 20:48

Dr.William A. Carter, the CEO of Hemispherx Biopharma shares his thoughts on the


Powered by Tengine/1.4.2 FDA delay, the flu pandemic and the future of his company. Late in the interview he also answers questions submitted to us by our readers. Certainly, the interview is filled with candid revelations and 301 Moved Permanently interesting nuggets of new information.

Warning: Due To Heavy Traffic And Length, The Screen May Not Load For A Few Seconds. Please Be Patient.
We also have an alternate feed available if you find that this feed is slow to load.

TRT: Approximately 45 Minutes






BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and

301 Moved Permanently

investor relation services from various entities and

The requested resource has been assigned a new permanent URI.

firms. Full disclosures should be read in the 'About Us Section'.


Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter

BioMedReports Abeona Announces FDA Allowance of (IND) for Phase 1/2 Clinical Study With ABO-101 Gene Therapy for Sanfilippo: https://t.co/Q4tDIzk0jB $ABEO
BioMedReports CEL-SCI Announces the Closing of Its $5 Million Registered Direct Offering: https://t.co/qL53OVHEp4 $CVM
BioMedReports Advanced Accelerator Applications preparing for Lutathera launch by scaling up production in Ivrea, Italy: https://t.co/42akkT1M4M $AAAP
BMR:1